迪瑞醫療(300396.SZ):華潤集團擬受讓不少於25%的股份 明起停牌
格隆匯 8 月 17日丨迪瑞醫療(300396.SZ)公佈,公司接到控股股東晉江瑞發投資有限公司(“晉江瑞發”)的通知,晉江瑞發擬將持有公司不少於25%以上股份轉讓給華潤集團全資控股的股權投資平台。
該事項可能涉及公司控制權的變更,此次交易需要取得國家市場監督管理總局反壟斷局的批准以及相關股權轉讓事項需取得深圳證券交易所的確認意見。截至目前,尚未簽署相關股權轉讓框架協議、意向書等。
經公司向深圳證券交易所申請,公司股票自2020年8月18日上午開市起停牌,預計停牌時間不超過五個交易日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.